Increases in drug prices are of concern to worldwide health systems

By HEOR Staff Writer

March 17, 2023

In surveys of ISPOR members, drug pricing was revealed to be a major concern, and one of the top 10 health economics and outcomes research issues influencing the availability of innovative treatments and healthcare decisions.

Despite the fascinating ways that different research studies proposed to understand the puzzle of drug pricing, it is evident that drug prices must factor in the research uncertainties and other costs in addition to the cost of clinical trials and production and should be set to yield an acceptable return on investment.

There has been a lot of discussion about the fairness of drug pricing. The concept is multifaceted, and when discussing it, drug characteristics and market forces must be included. This conversation is further complicated by the lack of transparency in drug pricing and the rise in drug prices.

It is likely that the debate will persist.

Reference url

Recent Posts

PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications

By João L. Carapinha

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies

By João L. Carapinha

April 23, 2026

Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...